ClinicalTrials.gg

TargetBeta

INSR

insulin receptor · also CD220 · CD molecules

8 programs in company-led studies act on INSR, from 5 companies: 1 in phase 3, 6 approved with new studies. Each with where its target was read from.

Programs

Furthest phase first. A target read by rule is marked rule (7 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.

ProgramCompanyFurthest phaseStudiesAlso acts onRead from
insulin degludecruleNovo Nordiskphase 41084 running–ChEMBL
Insulin AspartruleNovo Nordiskphase 41462 running–ChEMBL
insulin icodecruleNovo Nordiskphase 4302 running–ChEMBL
Insulin GlargineruleSanofiphase 41901 running–ChEMBL
InsulinrulePfizerphase 4501 running–ChEMBL
insulin glulisineruleSanofiphase 4430 running–ChEMBL
linsitinibruleAstellas Pharmaphase 3132 runningIGF1RChEMBL
LY3938577Eli Lillyphase 231 running–the company's pipeline

Also acted on by the same programs

Primary completions ahead

Each program’s next study to reach its primary completion, by the sponsor’s estimate.

What this can’t show

  • Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
  • A target read by rule can be wrong; each program’s page quotes the words it was read from.
  • “Acts on” does not say how: an agonist and an antagonist of the same receptor are listed together (avexitide blocks the GLP-1 receptor that semaglutide activates).
  • Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.